🤩SARCOMA AT PLENARY!🎗️
🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS
📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement
🎯 ORR: 9.3% vs 0%
⏳ OS trend favors abemaciclib (HR 0.55)
🔄 Crossover activity confirmed (mPFS 3.4 mo)
#ASCO26